Biological Matrix Supply Chain Shortages: More Matrices Are Now Rare-the Case for Surrogate Matrices.

Area of Science:

• Bioanalytical Sciences
• Drug Development
• Regulatory Affairs

Background:

• The COVID-19 pandemic significantly disrupted biological matrix supply chains due to increased demand and logistical challenges.
• Shortages in biological matrices can lead to substantial delays in pharmaceutical and biotechnology drug development programs.

Discussion:

• The use of surrogate matrices is increasingly necessary for pharmacokinetic (PK), immunogenicity, and biomarker assays when biological matrices are scarce.
• Regulatory authorities permit surrogate matrix use if scientifically justified, ensuring method validity for regulatory submissions.
• Innovative therapies like cell and gene therapy (C>) present unique challenges to existing matrix supply chains.

Key Insights:

• Appropriate selection and scientific justification are crucial for the successful implementation of surrogate matrices in bioanalytical methods.
• Proactive strategies, including advance planning and protocol adjustments, are essential for mitigating supply chain risks.
• Ethical considerations, such as obtaining informed consent for additional matrix draws or repurposing samples, must be addressed.

Outlook:

• Industry stakeholders are implementing mitigation strategies to enhance supply chain resilience for biological matrices.
• Collaboration between matrix suppliers and contract research organizations (CROs) is vital for addressing current and future supply chain strains.
• Anticipating future needs and adapting protocols will be key to ensuring uninterrupted drug development pipelines.